Celontin (Methsuximide) - Indications and Dosage

INDICATIONS AND USAGE

Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

DOSAGE AND ADMINISTRATION

Optimum dosage of Celontin must be determined by trial. A suggested dosage schedule is 300 mg per day for the first week. If required, dosage may be increased thereafter at weekly intervals by 300 mg per day for the three weeks following to a daily dosage of 1.2 g. Because therapeutic effect and tolerance vary among patients, therapy with Celontin must be individualized according to the response of each patient. Optimal dosage is that amount of Celontin which is barely sufficient to control seizures so that side effects may be kept to a minimum. The smaller capsule (150 mg) facilitates administration to small children.

Celontin may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal).

HOW SUPPLIED

N 0071-0525-24 (P-D 525)–Celontin Capsules, #1 capsule each containing 300 mg methsuximide; bottles of 100.

N 0071-0537-24 (P-D 537)–Celontin Capsules, Half-Strength, #3 capsule each containing 150 mg methsuximide; bottles of 100.

Store at 25°C (77°F); excursions permitted to 15—30°C (59—86°F) [see USP Controlled Room Temperature].

Protect from light and moisture. Protect from excessive heat 40°C (104°F).

Rx only

LAB-0156-3.0

April 2009